Johnson & Johnson agreed to buy biotechnology startup Proteologix for $850 million in cash, gaining a portfolio of bispecific antibodies the privately held company has been developing for immune diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,